Oncovir

Oncovir is a privately held, clinical-phase biotech focused on a single, versatile asset: Hiltonol® (Poly ICLC). This stabilized double-stranded RNA compound acts as a broad immune activator, functioning as a 'danger signal' to stimulate the immune system against tumors and pathogens. The company's strategy involves advancing Hiltonol® through partnerships in various combination therapies for solid cancers and infectious diseases, positioning it as a potential backbone for next-generation immunotherapies and vaccine adjuvants. Oncovir operates as a lean organization, manufacturing GMP-grade material and seeking strategic collaborations to fund and execute clinical development.

Hiltonol® (Poly ICLC), a stabilized synthetic double-stranded RNA (dsRNA) viral mimic that broadly activates innate and adaptive immunity via TLR3 and MDA5 pathways. It functions as an immunomodulator and 'danger signal' to stimulate dendritic cells, NK cells, T-cells, and interferon production.

In immuno-oncology, Hiltonol® competes with other innate immune activators like STING agonists, TLR agonists (e.g., TLR9), and oncolytic viruses. As a vaccine adjuvant, it competes with established adjuvants (AS01, MF59) and novel platforms. Its differentiation lies in its long clinical history, dual TLR3/MDA5 mechanism, and versatility across oncology and infectious disease applications.